exactly are bnAbs and how do they work? Broadly neutralizing antibodies, or bnAbs, are a rare type of immune defense that can recognize and block a wide range of HIV variants. Unlike standard antibodies, which often only recognize a specific variant of the virus, bnAbs target parts of HIV that stay
May 16, 2025 at 4:05 PM
exactly are bnAbs and how do they work? Broadly neutralizing antibodies, or bnAbs, are a rare type of immune defense that can recognize and block a wide range of HIV variants. Unlike standard antibodies, which often only recognize a specific variant of the virus, bnAbs target parts of HIV that stay
GOOD NEWS! For the FIRST time ever, and after MORE THAN 30 YEARS of HIV vaccine clinical trials, researchers have developed a vaccine that has SUCCESSFULLY generated TIER 2 broadly neutralizing antibodies (bnAbs) against HIV and BLOCKS viral infection in vaccinated PEOPLE.
August 26, 2025 at 4:01 PM
GOOD NEWS! For the FIRST time ever, and after MORE THAN 30 YEARS of HIV vaccine clinical trials, researchers have developed a vaccine that has SUCCESSFULLY generated TIER 2 broadly neutralizing antibodies (bnAbs) against HIV and BLOCKS viral infection in vaccinated PEOPLE.
THIS IS HUGE! TWO Phase I HIV vaccine clinical trials have demonstrated that a stepwise mRNA-based vaccination strategy can SUCCESSFULLY activate AND advance immune responses toward producing broadly neutralizing antibodies (bnAbs), a CRITICAL milestone in HIV prevention. Let’s talk about that! 🧪🧵⬇️
May 16, 2025 at 4:00 PM
THIS IS HUGE! TWO Phase I HIV vaccine clinical trials have demonstrated that a stepwise mRNA-based vaccination strategy can SUCCESSFULLY activate AND advance immune responses toward producing broadly neutralizing antibodies (bnAbs), a CRITICAL milestone in HIV prevention. Let’s talk about that! 🧪🧵⬇️
THIS IS HUGE! Scientists at Duke University's Human Vaccine Institute have made a significant advance in the quest for an HIV vaccine, successfully developing a vaccine candidate that could help the immune system produce antibodies (bnAbs) needed to fight the virus. Let’s talk about that! 🧪🧵⬇️
January 20, 2025 at 5:00 PM
THIS IS HUGE! Scientists at Duke University's Human Vaccine Institute have made a significant advance in the quest for an HIV vaccine, successfully developing a vaccine candidate that could help the immune system produce antibodies (bnAbs) needed to fight the virus. Let’s talk about that! 🧪🧵⬇️
the same even as the virus mutates. Researchers have long viewed bnAbs as the immune system’s best shot at preventing HIV infection. The first step in helping the body produce bnAbs is through what’s known as a PRIMING vaccine- an initial dose designed to activate rare, naïve B-cells with the
May 16, 2025 at 4:05 PM
the same even as the virus mutates. Researchers have long viewed bnAbs as the immune system’s best shot at preventing HIV infection. The first step in helping the body produce bnAbs is through what’s known as a PRIMING vaccine- an initial dose designed to activate rare, naïve B-cells with the
animal models showing that the Asn332 glycan is underrepresented in transmitted or founder viruses, and infection with Asn332-glycan-deficient viruses has been associated with the later development of Asn332-dependent bNAbs in humans. In addition, two human V3-glycan bNAbs, EPTC112 and 007, were
May 14, 2026 at 4:06 PM
animal models showing that the Asn332 glycan is underrepresented in transmitted or founder viruses, and infection with Asn332-glycan-deficient viruses has been associated with the later development of Asn332-dependent bNAbs in humans. In addition, two human V3-glycan bNAbs, EPTC112 and 007, were
very challenging. The virus expertly evades the immune system by donning disguises, and it mutates rapidly, constantly switching up its look. Ideally, HIV vaccines will trigger the production of elusive broadly neutralizing antibodies, or bNabs- proteins that target relatively immutable bits of the
August 26, 2025 at 4:04 PM
very challenging. The virus expertly evades the immune system by donning disguises, and it mutates rapidly, constantly switching up its look. Ideally, HIV vaccines will trigger the production of elusive broadly neutralizing antibodies, or bNabs- proteins that target relatively immutable bits of the
vaccine development: how to efficiently elicit broadly neutralizing antibodies (bNAbs) capable of working against diverse HIV strains. Sequential immunization strategies, which use a series of engineered envelope proteins (Env) to produce antibody maturation, have shown some promise, but the need
May 14, 2026 at 4:05 PM
vaccine development: how to efficiently elicit broadly neutralizing antibodies (bNAbs) capable of working against diverse HIV strains. Sequential immunization strategies, which use a series of engineered envelope proteins (Env) to produce antibody maturation, have shown some promise, but the need
for repeated injections over long periods would make them impractical. Only a small number of these development attempts have consistently induced bNAbs in nonhuman primates. Even then, the responses have shown limited potency and breadth. For their candidate, researchers focused on one element of
May 14, 2026 at 4:06 PM
for repeated injections over long periods would make them impractical. Only a small number of these development attempts have consistently induced bNAbs in nonhuman primates. Even then, the responses have shown limited potency and breadth. For their candidate, researchers focused on one element of
GS-US-382-5445 is the first HIV cure trial conducted in Africa, and in an entirely female population!
Vesatolimod + 2 bNAbs (VRC07-525LD + CAP256V2LS) was well tolerated & yielded durable ART-free virological control in 20% & atypical rebound dynamics in 40%
#croi2025
Vesatolimod + 2 bNAbs (VRC07-525LD + CAP256V2LS) was well tolerated & yielded durable ART-free virological control in 20% & atypical rebound dynamics in 40%
#croi2025
March 10, 2025 at 6:18 PM
GS-US-382-5445 is the first HIV cure trial conducted in Africa, and in an entirely female population!
Vesatolimod + 2 bNAbs (VRC07-525LD + CAP256V2LS) was well tolerated & yielded durable ART-free virological control in 20% & atypical rebound dynamics in 40%
#croi2025
Vesatolimod + 2 bNAbs (VRC07-525LD + CAP256V2LS) was well tolerated & yielded durable ART-free virological control in 20% & atypical rebound dynamics in 40%
#croi2025
(boosters), guide those cells through a process of maturation toward producing HIV-targeting antibodies. Even though these trials weren’t intended to generate bnAbs themselves, they demonstrated that the vaccine strategy to deliver a series of different shots to guide the immune system to produce
May 16, 2025 at 4:06 PM
(boosters), guide those cells through a process of maturation toward producing HIV-targeting antibodies. Even though these trials weren’t intended to generate bnAbs themselves, they demonstrated that the vaccine strategy to deliver a series of different shots to guide the immune system to produce
found to neutralize HIV without contacting the Asn332 glycan. This provided evidence that Asn332-glycan-independent bNAbs COULD develop in humans. To test their hypothesis, researchers designed WIN332 as an Asn332-glycan-deficient priming immunogen and evaluated it in nonhuman primates. Their data
May 14, 2026 at 4:08 PM
found to neutralize HIV without contacting the Asn332 glycan. This provided evidence that Asn332-glycan-independent bNAbs COULD develop in humans. To test their hypothesis, researchers designed WIN332 as an Asn332-glycan-deficient priming immunogen and evaluated it in nonhuman primates. Their data
vaccine produced TWO TO THREE TIMES MORE unique B-cells than mice that received just one of the adjuvants. That increase in B-cell number and diversity boosts the chances that the vaccine could generate broadly neutralizing antibodies (bnAbs)- antibodies that can recognize a variety of strains of a
September 30, 2025 at 4:09 PM
vaccine produced TWO TO THREE TIMES MORE unique B-cells than mice that received just one of the adjuvants. That increase in B-cell number and diversity boosts the chances that the vaccine could generate broadly neutralizing antibodies (bnAbs)- antibodies that can recognize a variety of strains of a
bnAbs are the future for HIV - and the future is just about here
POZ reports RIO trial findings that experimental broadly neutralizing antibodies may work with some participants' immune responses to prolong HIV control; this is research, not a cure or routine care.
www.poz.com/article/teac...
www.poz.com/article/teac...
Teaching the Immune System to Control HIV
Working with a patient’s own immune response, therapeutic broadly neutralizing antibodies may prolong viral control.
www.poz.com
October 1, 2026 at 8:45 PM
bnAbs are the future for HIV - and the future is just about here
bnAbs. Named after a well-studied bnAb that neutralizes a wide range of HIV variants, VRC01-class antibodies block HIV from binding to a host cell’s entry receptor by targeting a region of HIV that rarely changes, despite the virus’s rapid mutation. Thus, these antibodies are considered among the
May 16, 2025 at 4:08 PM
bnAbs. Named after a well-studied bnAb that neutralizes a wide range of HIV variants, VRC01-class antibodies block HIV from binding to a host cell’s entry receptor by targeting a region of HIV that rarely changes, despite the virus’s rapid mutation. Thus, these antibodies are considered among the
bnAbs has great promise. This work builds on two key lines of earlier research results published in 2022 from the IAVI G001 clinical trial, which showed how a protein-based vaccine could successfully activate the rare immune cells needed to initiate bnAb development, and a series of four preclinical
May 16, 2025 at 4:06 PM
bnAbs has great promise. This work builds on two key lines of earlier research results published in 2022 from the IAVI G001 clinical trial, which showed how a protein-based vaccine could successfully activate the rare immune cells needed to initiate bnAb development, and a series of four preclinical
potential to eventually produce bnAbs. This approach is referred to as germline targeting. Most of you know that B-cells are a type of white blood cell that play a central role in the immune system by making antibodies that recognize and fight off viruses and other threats. Later vaccine doses
May 16, 2025 at 4:05 PM
potential to eventually produce bnAbs. This approach is referred to as germline targeting. Most of you know that B-cells are a type of white blood cell that play a central role in the immune system by making antibodies that recognize and fight off viruses and other threats. Later vaccine doses
Analysis of these responses showed that WIN332 elicited antibodies closely resembling potent human V3-glycan bNAbs. The data also found two distinct classes of antibodies: type-I antibodies that depend on the Asn332 glycan, AND a new type-II class of antibodies that remain glycan independent.
May 14, 2026 at 4:09 PM
Analysis of these responses showed that WIN332 elicited antibodies closely resembling potent human V3-glycan bNAbs. The data also found two distinct classes of antibodies: type-I antibodies that depend on the Asn332 glycan, AND a new type-II class of antibodies that remain glycan independent.
Nature research paper: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life
go.nature.com/46C1xWa
go.nature.com/46C1xWa
Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life - Nature
A single dose of an adeno-associated virus vector encoding an HIV-1 broadly neutralizing antibody given shortly after birth results in persistent antibody expression and protection from infection in rhesus macaque models of human HIV-1 transmission through breastfeeding and sexual intercourse.
go.nature.com
July 31, 2025 at 5:22 PM
Nature research paper: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life
go.nature.com/46C1xWa
go.nature.com/46C1xWa
LEN + 2 bNAbs teropavimab & zinlirvimab, call em TAB & ZAB, target gp120 CD4 binding site & v3 glycine on HIV-1 env. Low vs high dose ZAB groups, ppl susceptible to 1 or both bNAbs. 3 VFs 1 with emergent capsid RAMs.
#hivglasgow *hivglasgow
#hivglasgow *hivglasgow
November 11, 2024 at 9:36 AM
LEN + 2 bNAbs teropavimab & zinlirvimab, call em TAB & ZAB, target gp120 CD4 binding site & v3 glycine on HIV-1 env. Low vs high dose ZAB groups, ppl susceptible to 1 or both bNAbs. 3 VFs 1 with emergent capsid RAMs.
#hivglasgow *hivglasgow
#hivglasgow *hivglasgow
ONLY five to nine out of a panel of 337 strains were resistant to some extent at all, and the antibody possessed a nearly unprecedented breadth of neutralization. It also performed well against viruses ALREADY RESISTANT to other antibodies- neutralizing nearly 80% of viruses that evaded VRC01.
March 22, 2026 at 4:08 PM
ONLY five to nine out of a panel of 337 strains were resistant to some extent at all, and the antibody possessed a nearly unprecedented breadth of neutralization. It also performed well against viruses ALREADY RESISTANT to other antibodies- neutralizing nearly 80% of viruses that evaded VRC01.
Wissen über immunevasive Varianten vorhanden ist. Wir haben eine Strategie entwickelt, mit der wir gezielt nach potenten bnAbs suchen können, die sowohl gegen bestehende als auch gegen künftige SARS-CoV-2-Varianten wirksam sind, und zwar auf der Grundlage einer präzisen
April 19, 2024 at 5:03 PM
Wissen über immunevasive Varianten vorhanden ist. Wir haben eine Strategie entwickelt, mit der wir gezielt nach potenten bnAbs suchen können, die sowohl gegen bestehende als auch gegen künftige SARS-CoV-2-Varianten wirksam sind, und zwar auf der Grundlage einer präzisen
The study has been published in Nature Immunology. YES, it is PEER-REVIEWED.
• www.nature.com/articles/s41...
NOTE: THIS IS PRECLINICAL.
🧪🧵⬇️
• www.nature.com/articles/s41...
NOTE: THIS IS PRECLINICAL.
🧪🧵⬇️
May 14, 2026 at 4:02 PM
The study has been published in Nature Immunology. YES, it is PEER-REVIEWED.
• www.nature.com/articles/s41...
NOTE: THIS IS PRECLINICAL.
🧪🧵⬇️
• www.nature.com/articles/s41...
NOTE: THIS IS PRECLINICAL.
🧪🧵⬇️
#IDSky
Fascinating article in CMR looking at mRNA technology to target HIV-1 env to induce B and T cell responses.
Where do you think the promise lies in future HIV prevention? Vaccine, bNABs or LA- PREP (lenacapavir)?
doi.org/10.1128/cmr....
Fascinating article in CMR looking at mRNA technology to target HIV-1 env to induce B and T cell responses.
Where do you think the promise lies in future HIV prevention? Vaccine, bNABs or LA- PREP (lenacapavir)?
doi.org/10.1128/cmr....
November 18, 2024 at 1:31 AM
#IDSky
Fascinating article in CMR looking at mRNA technology to target HIV-1 env to induce B and T cell responses.
Where do you think the promise lies in future HIV prevention? Vaccine, bNABs or LA- PREP (lenacapavir)?
doi.org/10.1128/cmr....
Fascinating article in CMR looking at mRNA technology to target HIV-1 env to induce B and T cell responses.
Where do you think the promise lies in future HIV prevention? Vaccine, bNABs or LA- PREP (lenacapavir)?
doi.org/10.1128/cmr....
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
March 10, 2025 at 6:48 PM
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.